The role of fibrinogen-like protein 1 in immune escape and tumor growth mechanism of Warthin's tumor
Downloads
Background: One of the benign tumors of the salivary glands is Warthin's Tumor (WT), which consists of cystic bilayer papillary epithelial cells accompanied by the presence of a lymphoid stroma. Several cases have been reported to turn malignant. One of the markers developed to identify tumor proteins is fibrinogen-like protein 1 (FGL1). Along with lymphocyte-activation gene 3 (LAG-3), FGL1 establishes an immune checkpoint pathway that plays a role in the mechanism of tumor immune escape. Not much has been reported regarding FGL1 expression in WT, but some studies have reported that its expression is associated with tumor growth. Purpose: This study aims to analyze the location of FGL1 expression in WT and its relation to the mechanism of tumor immune release through the interaction between FGL1 and LAG-3. Methods: Cases of WT (n = 11) and breast cancer (n = 1) were used as positive controls. All cases were stained with hematoxylin-eosin and Recombinant Anti-FGL1 antibody. The FGL1 expression was observed in the cell membrane, cytoplasm, and lymphoid stroma. The results are presented in the form of figures. Results: All cases of WT expressed FGL1 in the cell membrane, cytoplasm, and lymphoid stroma. Its expression in the cell membrane and cytoplasm is possibly related to the process of tumorigenesis and the increasing size of the lesion. Additionally, its expression is seen in the lymphoid stroma, which is closely related to immune escape by inhibiting lymphocytes against tumor cells. Conclusion: Warthin's tumor cells express FGL1, and this expression plays a role in tumor immune escape mechanisms and tumor growth.
Downloads
Chan W-H, Lee K-W, Chiang F-Y, Ho K-Y, Chai C-Y, Kuo W-R. Features of parotid gland diseases and surgical results in southern Taiwan. Kaohsiung J Med Sci. 2010; 26(9): 483–92. doi: https://doi.org/10.1016/S1607-551X(10)70076-0
Song K, Cotelingam JD, Lowery-Nordberg M, Sun W. Characterization of the lymphoid stroma in Warthin's tumor of salivary gland by immunohistochemistry, heavy chain gene and Bcl-2 gene rearrangement. Am J Transl Res. 2009; 1(4): 352–7. pubmed: http://www.ncbi.nlm.nih.gov/pubmed/19956447
Kuzenko Y V., Romanuk AM, Dyachenko OO, Hudymenko O. Pathogenesis of Warthin's tumors. Interv Med Appl Sci. 2016; 8(2): 41–8. doi: https://doi.org/10.1556/1646.8.2016.2.2
Rachmad N, Gofur P, Rachmadani A, Gofur P, Nur R, Putra R. Favorable treatment for rare case tumor in oral cavity: A whartin's tumor review article. Int J Dent Sci. 2021; 3(1): 26–31. web: https://www.dentaljournal.in/archives/2021/vol3/issue1/3-1-13
Raghu AR, Rehani S, Bishen KA, Sagari S. Warthin's tumour: A case report and review on pathogenesis and its histological subtypes. J Clin Diagn Res. 2014; 8(9): ZD37-40. doi: https://doi.org/10.7860/JCDR/2014/8503.4908
Shou L, Chen X, Yang J, Jiang Y. Malignant transformation of Warthin's tumor into squamous cell carcinoma: A case report. Oncol Lett. 2022; 24(1): 201. doi: https://doi.org/10.3892/ol.2022.13322
Chulam TC, Noronha Francisco AL, Goncalves Filho J, Pinto Alves CA, Kowalski LP. Warthin's tumour of the parotid gland: our experience. Acta Otorhinolaryngol Ital. 2013; 33(6): 393–7. web: http://www.ncbi.nlm.nih.gov/pubmed/24376295
Nguyen KA, Thai TA, Giang CT. Malignant transformation in a parotid Warthin's tumor: Clinical features and histopathological examination. J Cancer Biol Res. 2018; 6(1): 1115. web: https://www.jscimedcentral.com/public/assets/articles/cancerbiology-6-1115.pdf
Shirai K, Kawashima M, Saitoh J-I, Abe T, Fukata K, Shigeta Y, Irie D, Shiba S, Okano N, Ohno T, Nakano T. Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot study. PLoS One. 2017; 12(4): e0175589. doi: https://doi.org/10.1371/journal.pone.0175589
Valdez JA, Brennan MT. Impact of oral cancer on quality of life. Dent Clin North Am. 2018; 62(1): 143–54. doi: https://doi.org/10.1016/j.cden.2017.09.001
Li N, Hou X, Huang S, Tai R, Lei L, Li S, Abuliz A, Wang G, Yang S. Biomarkers related to immune checkpoint inhibitors therapy. Biomed Pharmacother. 2022; 147: 112470. doi: https://doi.org/10.1016/j.biopha.2021.112470
Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020; 8: 34. doi: https://doi.org/10.1186/s40364-020-00209-0
Huo J-L, Wang Y-T, Fu W-J, Lu N, Liu Z-S. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022; 13: 956090. doi: https://doi.org/10.3389/fimmu.2022.956090
Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother cancer. 2020; 8(2). doi: https://doi.org/10.1136/jitc-2020-001014
Qotrunnada AN, Indriana T, Kosasih J, Margaretha M, Syafriadi M. Role of cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression in the pathogenesis of Warthin's tumor growth. Dent J. 2022; 55(4): 194–9. doi: https://doi.org/10.20473/j.djmkg.v55.i4.p194-199
Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol. 2021; 14(1): 1–17. doi: https://doi.org/10.1186/s13045-021-01161-8
Shi A-P, Tang X-Y, Xiong Y-L, Zheng K-F, Liu Y-J, Shi X-G, Lv Y, Jiang T, Ma N, Zhao J-B. Immune checkpoint LAG3 and its ligand FGL1 in cancer. Front Immunol. 2022; 12: 785091. doi: https://doi.org/10.3389/fimmu.2021.785091
Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019; 176(1–2): 334-347.e12. doi: https://doi.org/10.1016/j.cell.2018.11.010
Yu J, Li J, Shen J, Du F, Wu X, Li M, Chen Y, Cho CH, Li X, Xiao Z, Zhao Y. The role of fibrinogen-like proteins in cancer. Int J Biol Sci. 2021; 17(4): 1079–87. doi: https://doi.org/10.7150/ijbs.56748
Lin W-W, Ho K-W, Su H-H, Fang T-F, Tzou S-C, Chen I-J, Lu Y-C, Chang M-S, Tsai Y-C, Liu E-S, Su Y-C, Wang Y-T, Cheng T-L, Huang H-K. Fibrinogen-like protein 1 serves as an anti-inflammatory agent for collagen-induced arthritis therapy in mice. Front Immunol. 2021; 12: 767868. doi: https://doi.org/10.3389/fimmu.2021.767868
Graydon CG, Mohideen S, Fowke KR. LAG3's enigmatic mechanism of action. Front Immunol. 2021; 11: 615317. doi: https://doi.org/10.3389/fimmu.2020.615317
Watowich MB, Gilbert MR, Larion M. T cell exhaustion in malignant gliomas. Trends in cancer. 2023; 9(4): 270–92. doi: https://doi.org/10.1016/j.trecan.2022.12.008
Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin Immunol. 2019; 42: 101305. doi: https://doi.org/10.1016/j.smim.2019.101305
Copyright (c) 2024 Dental Journal
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- Every manuscript submitted to must observe the policy and terms set by the Dental Journal (Majalah Kedokteran Gigi).
- Publication rights to manuscript content published by the Dental Journal (Majalah Kedokteran Gigi) is owned by the journal with the consent and approval of the author(s) concerned.
- Full texts of electronically published manuscripts can be accessed free of charge and used according to the license shown below.
- The Dental Journal (Majalah Kedokteran Gigi) is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
